scholarly journals Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus

npj Vaccines ◽  
2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Fangfang Dong ◽  
Dandan Li ◽  
Dan Wen ◽  
Suhua Li ◽  
Chaoyue Zhao ◽  
...  
Keyword(s):  
Single Dose ◽  
Complete Protection ◽  
Severe Fever

scholarly journals Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice

2019 ◽  
Vol 8 (1) ◽  
pp. 575-578 ◽  
Author(s):  
Florine E. M. Scholte ◽  
Jessica R. Spengler ◽  
Stephen R. Welch ◽  
Jessica R. Harmon ◽  
JoAnn D. Coleman-McCray ◽  
...  
Keyword(s):  
Single Dose ◽  
Hemorrhagic Fever ◽  
Fever Virus ◽  
Complete Protection ◽  
Crimean Congo Hemorrhagic Fever ◽  
Hemorrhagic Fever Virus ◽  
Replicon Particle

scholarly journals A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters

2019 ◽  
Vol 13 (6) ◽  
pp. e0007462 ◽  
Author(s):  
Neeltje van Doremalen ◽  
Teresa Lambe ◽  
Sarah Sebastian ◽  
Trenton Bushmaker ◽  
Robert Fischer ◽  
...  
Keyword(s):  
Single Dose ◽  
Complete Protection ◽  
Golden Hamsters ◽  
Syrian Golden Hamsters ◽  
Vectored Vaccine

The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: An exploratory trial HGCSG0703.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 589-589
Author(s):  
S. Yuki ◽  
H. Nakatsumi ◽  
M. Tateyama ◽  
Y. Uehata ◽  
M. Kudo ◽  
...  
Keyword(s):  
Single Dose ◽  
Rescue Therapy ◽  
Optimal Dose ◽  
Nausea And Vomiting ◽  
Complete Protection ◽  
Chi Square ◽  
Dose Period ◽  
Chi Square Test ◽  
Group A ◽  
Group B

589 Background: Indisetron is a 5-HT3 receptor antagonist which shows also 5-HT4 antagonistic activity, that had approved in 2004 by Japan's PMDA. There are no recommendations of prophylactic regimens for preventing nausea and vomiting induced by FOLFOX therapy. To explore the optimal dose period of indisetron tablets during mFOLFOX6, we designed the study to compare the antiemetic efficacy and safety of 3-day regimen of indisetron with a single dose regimen. Methods: Advanced colorectal cancer patients who were treated with mFOLFOX6 (+/- bevacizumab) as first-line chemotherapy were enrolled in this study. They were randomly assigned to Group A (3-day of indisetron) or Group B (a single dose of indisetron). Dexamethazone (8mg) was also administered intravenously in both groups before administering of oxaliplatin. The follow-up period was 5 days from the start of chemotherapy. The primary endpoint was complete protection from vomiting, and secondary endpoints were complete protection from nausea, no use of rescue therapy, and severe adverse events. Results: Of 45 patients enrolled in this trial, 42 (93.3%) were assessable. The proportions of patients with complete protection from vomiting were 85.7% in Group A, and 81.0% in Group B (p=1.000; Fisher's exact test). The proportions of patients with complete protection from nausea were 47.6% in each group (p=1.000; chi-square test). The no rescue therapy rates were 66.7% in Group A, and 57.1% in Group B (p=0.525; chi-square test). No severe adverse events were observed in both groups. Conclusions: We suggested that the efficacy of a single dose of indisetron might be equivalent of 3-day regimen for preventing from nausea and vomiting induced by mFOLFOX6. [Table: see text]

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.

1989 ◽  
Vol 7 (11) ◽  
pp. 1693-1700 ◽  
Author(s):  
F Roila ◽  
M Tonato ◽  
C Basurto ◽  
M Picciafuoco ◽  
S Bracarda ◽  
...  
Keyword(s):  
Single Dose ◽  
Dose Schedule ◽  
High Dose ◽  
Oncology Group ◽  
Complete Protection ◽  
Double Blind ◽  
Younger Patients ◽  
Multifactorial Analysis ◽  
Significant Difference ◽  
Efficacy Of Treatment

Despite treatment, emesis remains a major problem with cisplatin (CDDP) chemotherapy. Reasons for variability in antiemetic response among patients and in subsequent cycles are largely unknown and toxicity is sometimes severe. We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B). Three hundred sixty-seven consecutive patients treated with various chemotherapy combinations containing CDDP were studied. Complete protection from vomiting/nausea was, at first cycle, 72.5%/79.5% with treatment B and 55.8%/65.1% with treatment A, a statistically significant difference (P less than .002/P less than .005). In subsequent cycles, protection from emesis significantly decreased with no difference between the two treatments. Multifactorial analysis shows that women, younger patients, outpatients, and patients who experienced emesis in previous cycles were at higher risk of suffering nausea and/or vomiting. Both regimens were well tolerated, but patients treated with treatment B had significantly less extrapyramidal reactions (1.7%/6.1%, P = .053). Treatment B is preferred due to its greater efficacy and lower incidence of extrapyramidal reactions. Trials on antiemetic therapy should take into account the important variables able to influence the efficacy of treatment. There is still a need for improving prevention of emesis in CDDP-treated patients.

scholarly journals Complete Protection from Papillomavirus Challenge after a Single Vaccination with a Vesicular Stomatitis Virus Vector Expressing High Levels of L1 Protein

2004 ◽  
Vol 78 (6) ◽  
pp. 3196-3199 ◽  
Author(s):  
Anjeanette Roberts ◽  
Jon D. Reuter ◽  
Jean H. Wilson ◽  
Stuart Baldwin ◽  
John K. Rose
Keyword(s):  
Single Dose ◽  
Vesicular Stomatitis Virus ◽  
Complete Protection ◽  
Downstream Site ◽  
Upstream Site ◽  
Cottontail Rabbit ◽  
Single Vaccination ◽  
Vesicular Stomatitis ◽  
L1 Protein ◽  
Dose Vaccine

ABSTRACT We generated an attenuated, recombinant vesicular stomatitis virus (VSV) expressing high levels of the cottontail rabbit papillomavirus (CRPV) L1 protein from an upstream site in the VSV genome. Rabbits vaccinated once with this VSV-L1 recombinant produced high levels of anti-L1 antibody and were completely protected against papilloma formation after challenge with CRPV. In contrast, animals vaccinated only once with a VSV vector expressing lower levels of L1 from a downstream site in the VSV genome generated lower levels of L1 antibody and demonstrated only incomplete protection from papilloma formation after challenge. We conclude that the level of L1 protein expression is critical in generating complete immunity with a single-dose vaccine.

Randomized, Double-Blind, Dose-Finding Study of Dexamethasone in Preventing Acute Emesis Induced by Anthracyclines, Carboplatin, or Cyclophosphamide:

2004 ◽  
Vol 22 (4) ◽  
pp. 725-729 ◽  
Author(s):  
Keyword(s):  
Single Dose ◽  
Dose Finding ◽  
Complete Protection ◽  
Double Blind ◽  
Acute Emesis ◽  
Intention To Treat ◽  
Finding Study ◽  
Dose Finding Study ◽  
To Receive ◽  
Different Doses

Purpose Different doses and schedules of dexamethasone, combined with a 5-HT3 antagonist, are used to prevent acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. Therefore, we planned a randomized, double-blind, dose finding study aimed to identify the preferred dose and schedule of dexamethasone. Patients and Methods All consecutive chemotherapy-naive patients enrolled onto study were randomly assigned to receive for the prevention of acute emesis, during the first 24 hours, one of the following dexamethasone regimens, in combination with ondansetron 8 mg intravenously (IV): for arm A, 8 mg IV before chemotherapy plus 4 mg orally every 6 hours for four doses, starting at the same time of the chemotherapy; for arm B, 24 mg IV single dose before chemotherapy; and for arm C, 8 mg IV single dose before chemotherapy. All patients received from day 2 to 5 oral dexamethasone 4 mg bid. Results A total of 587 patients were enrolled, and 585 were assessed according to the intention-to-treat principle (195 patients in each arm). The rate of complete protection from acute vomiting and nausea, respectively, was not significantly different among the three groups (arm A, 84.6% and 66.7%; arm B, 83.6% and 56.9%; arm C, 89.2% and 61.0%), nor was the rate of complete protection from delayed vomiting and nausea, respectively (arm A, 81.0% and 46.7%; arm B, 81.3% and 45.1%; arm C, 79.8% and 46.1%). The incidence of delayed vomiting and nausea was strictly dependent on the presence of acute vomiting and nausea. Adverse events were mild and not significantly different among the three groups. Conclusion Dexamethasone 8 mg single dose IV before chemotherapy, in combination with a 5-HT3 antagonist, should be considered the preferred dose to prevent acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide.

scholarly journals Comparative Evaluation of Immune Responses and Protection of Chitosan Nanoparticles and Oil-Emulsion Adjuvants in Avian Coronavirus Inactivated Vaccines in Chickens

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1457
Author(s):  
Priscila Diniz Lopes ◽  
Cintia Hiromi Okino ◽  
Filipe Santos Fernando ◽  
Caren Pavani ◽  
Viviane Casagrande Mariguela ◽  
...  
Keyword(s):  
Single Dose ◽  
Immune Responses ◽  
Chitosan Nanoparticles ◽  
Single Administration ◽  
Complete Protection ◽  
Igg Antibody ◽  
Oil Emulsion ◽  
Inactivated Vaccines ◽  
Protection Against Infection ◽  
Antibody Levels

Efficient vaccines are the main strategy to control the avian coronavirus (AvCoV), although several drawbacks related to traditional attenuated and inactivated vaccines have been reported. These counterpoints highlight the importance of developing new alternative vaccines against AvCoV, especially those able to induce long-lasting immune responses. This study evaluated and compared two inactivated vaccines formulated with AvCoV BR-I variants, one composed of chitosan nanoparticles (AvCoV-CS) and the second by Montanide oily adjuvant (AvCoV-O). Both developed vaccines were administered in a single dose or associated with the traditional Mass attenuated vaccine. The AvCoV-CS vaccine administered alone or associated with the Mass vaccine was able to induce strong humoral and cell-mediated immune (CMI) responses and complete protection against IBV virulent infection, wherein single administration was characterized by high IgA antibody levels in the mucosa, whereas when associated with the Mass vaccine, the serum IgG antibody was predominantly observed. On the other hand, single administration of the oily vaccine presented poor humoral and CMI responses and consequently incomplete protection against virulent challenge, but when associated with the Mass vaccine, immune responses were developed, and complete protection against infection was observed. Both of our experimental vaccines were able to induce full protection against virulent IBV challenge. A single dose of AvCoV-CS vaccine was sufficient to achieve complete protection, while AvCoV-O required a previous priming by a Mass strain to complete the protection.

scholarly journals Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice

2020 ◽  
Vol 14 (3) ◽  
pp. e0007813 ◽  
Author(s):  
Jun-Gu Kang ◽  
Kyeongseok Jeon ◽  
Hooncheol Choi ◽  
Yuri Kim ◽  
Hong-Il Kim ◽  
...  
Keyword(s):  
Knockout Mice ◽  
Plasmid Dna ◽  
Dna Encoding ◽  
Complete Protection ◽  
Single Plasmid ◽  
Severe Fever

scholarly journals Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice

2019 ◽  
Author(s):  
Jun-Gu Kang ◽  
Kyeongseok Jeon ◽  
Hooncheol Choi ◽  
Yuri Kim ◽  
Hong-Il Kim ◽  
...  
Keyword(s):  
T Cell ◽  
Plasmid Dna ◽  
T Cell Responses ◽  
Cell Mediated Immunity ◽  
Dna Encoding ◽  
Complete Protection ◽  
Neutralizing Activity ◽  
Cell Responses ◽  
Viral Antigens ◽  
Severe Fever

AbstractSevere fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease caused by SFTS virus (SFTSV) infection. Despite a gradual increase of SFTS cases and high mortality in endemic regions, no specific viral therapy nor vaccine is available. Here, we developed a single recombinant plasmid DNA encoding SFTSV genes, Gn and Gc together with NP-NS fusion antigen, as a vaccine candidate. The viral antigens were fused with Fms-like tyrosine kinase-3 ligand (Flt3L) and IL-12 gene was incorporated into the plasmid to enhance cell-mediated immunity. Vaccination with the DNA provides complete protection of IFNAR KO mice upon lethal SFTSV challenge, whereas immunization with a plasmid without IL-12 gene resulted in partial protection. Since we failed to detect antibodies against surface glycoproteins, Gn and Gc, in the immunized mice, antigen-specific cellular immunity, as confirmed by enhanced antigen-specific T cell responses, might play major role in protection. Finally, we evaluated the degree of protective immunity provided by protein immunization of the individual glycoprotein, Gn or Gc. Although both protein antigens induced a significant level of neutralizing activity against SFTSV, Gn vaccination resulted in relatively higher neutralizing activity and better protection than Gc vaccination. However, both antigens failed to provide complete protection. Given that DNA vaccines have failed to induce sufficient immunogenicity in human trials when compared to protein vaccines, optimal combinations of DNA and protein elements, proper selection of target antigens, and incorporation of efficient adjuvant, need to be further investigated for SFTSV vaccine development.Author summarySevere fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infection endemic to East Asia including China, Korea, and Japan. Gradual rise of disease incidence and relatively high mortality have become a serious public health problem in the endemic countries. In this study, we developed a recombinant plasmid DNA encoding four antigens, Gn, Gc, NP, and NS, of SFTS virus (SFTSV) as a vaccine candidate. In order to enhance cell-mediated immunity, the viral antigens were fused with Flt3L and IL-2 gene was incorporated into the plasmid. Immunization with the DNA vaccine provides complete protection against lethal SFTSV infection in IFNAR KO mice. Antigen-specific T cell responses might play a major role in the protection since we observed enhanced T cell responses specific to the viral antigens but failed to detect neutralizing antibody in the immunized mice. When we immunized with either viral glycoprotein, Gn protein induced relatively higher neutralizing activity and better protection against SFTSV infection than Gc antigen, but neither generated complete protection. Therefore, an optimal combination of DNA and protein elements, as well as proper selection of target antigens, might be required to produce an effective SFTSV vaccine.

Sign in / Sign up

Export Citation Format

Share Document